Evaluation of a novel kallikrein inhibitor on hemostatic activation in vitro

Kenichi A. Tanaka, Fania Szlam, Nobuyuki Katori, J. David Vega, Jerrold H. Levy

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: DX-88 is a potent kallikrein inhibitor that is being studied for the treatment of hereditary angioedema (HAE) and represents a potential alternative to aprotinin in cardiac surgical patients. The current study was designed to evaluate in vitro effects of DX-88 on coagulation in comparison with aprotinin. Methods: Blood samples were obtained from consented 12 healthy volunteers. DX-88 or aprotinin was added to blood at 200 and 800 kallikrein inhibitory units (KIU) per milliliter for aprotinin, and at 1.1, 2.2, or 8.8 μg/ml for DX-88. Thromboelastography (TEG®) was performed using celite, kaolin, or tissue factor (TF) activation. Kaolin-based activated clotting times (ACTs) were measured at different heparin levels. The whole blood prothrombin time (PT)/PTT values were also measured. The endogenous thrombin generation was assessed with a fluorogenic assay using platelet-poor plasma (PPP). Results: With celite and kaolin activation of TEG, the reaction time was prolonged with DX-88 and aprotinin. With tissue factor activation, TEG parameters were not affected. DX-88 caused dose-dependent kaolin-ACT prolongation that was augmented by increasing doses of heparin. DX-88 or aprotinin had no significant effects on the PT values, but PTT values were dose-dependently prolonged. Both agents delayed the onset of thrombin generation when PTT reagent was used as a trigger, whereas no change was observed when tissue factor was used. Conclusion; We found that DX-88 delayed contact activator induced coagulation without affecting tissue factor mediated coagulation. For evaluation of coagulation during DX-88 therapy, the use of PT or tissue factor-activated TEG may be preferable.

Original languageEnglish
Pages (from-to)333-339
Number of pages7
JournalThrombosis Research
Volume113
Issue number5
DOIs
Publication statusPublished - 2004
Externally publishedYes

Fingerprint

Kallikreins
Aprotinin
Hemostatics
Thrombelastography
Thromboplastin
Kaolin
Prothrombin Time
Diatomaceous Earth
Thrombin
Heparin
Hereditary Angioedemas
In Vitro Techniques
Healthy Volunteers
Blood Platelets
Therapeutics

Keywords

  • Aprotinin
  • DX-88
  • Kallikrein inhibitor

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Hematology

Cite this

Tanaka, K. A., Szlam, F., Katori, N., Vega, J. D., & Levy, J. H. (2004). Evaluation of a novel kallikrein inhibitor on hemostatic activation in vitro. Thrombosis Research, 113(5), 333-339. https://doi.org/10.1016/j.thromres.2004.03.022

Evaluation of a novel kallikrein inhibitor on hemostatic activation in vitro. / Tanaka, Kenichi A.; Szlam, Fania; Katori, Nobuyuki; Vega, J. David; Levy, Jerrold H.

In: Thrombosis Research, Vol. 113, No. 5, 2004, p. 333-339.

Research output: Contribution to journalArticle

Tanaka, KA, Szlam, F, Katori, N, Vega, JD & Levy, JH 2004, 'Evaluation of a novel kallikrein inhibitor on hemostatic activation in vitro', Thrombosis Research, vol. 113, no. 5, pp. 333-339. https://doi.org/10.1016/j.thromres.2004.03.022
Tanaka, Kenichi A. ; Szlam, Fania ; Katori, Nobuyuki ; Vega, J. David ; Levy, Jerrold H. / Evaluation of a novel kallikrein inhibitor on hemostatic activation in vitro. In: Thrombosis Research. 2004 ; Vol. 113, No. 5. pp. 333-339.
@article{341ce6ea6bdf4f9cb106d3cb19fdc5a5,
title = "Evaluation of a novel kallikrein inhibitor on hemostatic activation in vitro",
abstract = "Background: DX-88 is a potent kallikrein inhibitor that is being studied for the treatment of hereditary angioedema (HAE) and represents a potential alternative to aprotinin in cardiac surgical patients. The current study was designed to evaluate in vitro effects of DX-88 on coagulation in comparison with aprotinin. Methods: Blood samples were obtained from consented 12 healthy volunteers. DX-88 or aprotinin was added to blood at 200 and 800 kallikrein inhibitory units (KIU) per milliliter for aprotinin, and at 1.1, 2.2, or 8.8 μg/ml for DX-88. Thromboelastography (TEG{\circledR}) was performed using celite, kaolin, or tissue factor (TF) activation. Kaolin-based activated clotting times (ACTs) were measured at different heparin levels. The whole blood prothrombin time (PT)/PTT values were also measured. The endogenous thrombin generation was assessed with a fluorogenic assay using platelet-poor plasma (PPP). Results: With celite and kaolin activation of TEG, the reaction time was prolonged with DX-88 and aprotinin. With tissue factor activation, TEG parameters were not affected. DX-88 caused dose-dependent kaolin-ACT prolongation that was augmented by increasing doses of heparin. DX-88 or aprotinin had no significant effects on the PT values, but PTT values were dose-dependently prolonged. Both agents delayed the onset of thrombin generation when PTT reagent was used as a trigger, whereas no change was observed when tissue factor was used. Conclusion; We found that DX-88 delayed contact activator induced coagulation without affecting tissue factor mediated coagulation. For evaluation of coagulation during DX-88 therapy, the use of PT or tissue factor-activated TEG may be preferable.",
keywords = "Aprotinin, DX-88, Kallikrein inhibitor",
author = "Tanaka, {Kenichi A.} and Fania Szlam and Nobuyuki Katori and Vega, {J. David} and Levy, {Jerrold H.}",
year = "2004",
doi = "10.1016/j.thromres.2004.03.022",
language = "English",
volume = "113",
pages = "333--339",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - Evaluation of a novel kallikrein inhibitor on hemostatic activation in vitro

AU - Tanaka, Kenichi A.

AU - Szlam, Fania

AU - Katori, Nobuyuki

AU - Vega, J. David

AU - Levy, Jerrold H.

PY - 2004

Y1 - 2004

N2 - Background: DX-88 is a potent kallikrein inhibitor that is being studied for the treatment of hereditary angioedema (HAE) and represents a potential alternative to aprotinin in cardiac surgical patients. The current study was designed to evaluate in vitro effects of DX-88 on coagulation in comparison with aprotinin. Methods: Blood samples were obtained from consented 12 healthy volunteers. DX-88 or aprotinin was added to blood at 200 and 800 kallikrein inhibitory units (KIU) per milliliter for aprotinin, and at 1.1, 2.2, or 8.8 μg/ml for DX-88. Thromboelastography (TEG®) was performed using celite, kaolin, or tissue factor (TF) activation. Kaolin-based activated clotting times (ACTs) were measured at different heparin levels. The whole blood prothrombin time (PT)/PTT values were also measured. The endogenous thrombin generation was assessed with a fluorogenic assay using platelet-poor plasma (PPP). Results: With celite and kaolin activation of TEG, the reaction time was prolonged with DX-88 and aprotinin. With tissue factor activation, TEG parameters were not affected. DX-88 caused dose-dependent kaolin-ACT prolongation that was augmented by increasing doses of heparin. DX-88 or aprotinin had no significant effects on the PT values, but PTT values were dose-dependently prolonged. Both agents delayed the onset of thrombin generation when PTT reagent was used as a trigger, whereas no change was observed when tissue factor was used. Conclusion; We found that DX-88 delayed contact activator induced coagulation without affecting tissue factor mediated coagulation. For evaluation of coagulation during DX-88 therapy, the use of PT or tissue factor-activated TEG may be preferable.

AB - Background: DX-88 is a potent kallikrein inhibitor that is being studied for the treatment of hereditary angioedema (HAE) and represents a potential alternative to aprotinin in cardiac surgical patients. The current study was designed to evaluate in vitro effects of DX-88 on coagulation in comparison with aprotinin. Methods: Blood samples were obtained from consented 12 healthy volunteers. DX-88 or aprotinin was added to blood at 200 and 800 kallikrein inhibitory units (KIU) per milliliter for aprotinin, and at 1.1, 2.2, or 8.8 μg/ml for DX-88. Thromboelastography (TEG®) was performed using celite, kaolin, or tissue factor (TF) activation. Kaolin-based activated clotting times (ACTs) were measured at different heparin levels. The whole blood prothrombin time (PT)/PTT values were also measured. The endogenous thrombin generation was assessed with a fluorogenic assay using platelet-poor plasma (PPP). Results: With celite and kaolin activation of TEG, the reaction time was prolonged with DX-88 and aprotinin. With tissue factor activation, TEG parameters were not affected. DX-88 caused dose-dependent kaolin-ACT prolongation that was augmented by increasing doses of heparin. DX-88 or aprotinin had no significant effects on the PT values, but PTT values were dose-dependently prolonged. Both agents delayed the onset of thrombin generation when PTT reagent was used as a trigger, whereas no change was observed when tissue factor was used. Conclusion; We found that DX-88 delayed contact activator induced coagulation without affecting tissue factor mediated coagulation. For evaluation of coagulation during DX-88 therapy, the use of PT or tissue factor-activated TEG may be preferable.

KW - Aprotinin

KW - DX-88

KW - Kallikrein inhibitor

UR - http://www.scopus.com/inward/record.url?scp=2942618600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942618600&partnerID=8YFLogxK

U2 - 10.1016/j.thromres.2004.03.022

DO - 10.1016/j.thromres.2004.03.022

M3 - Article

VL - 113

SP - 333

EP - 339

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 5

ER -